Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Touts Alli As Tip Of OTC Strength, Reaffirms Consumer Commitment

This article was originally published in The Tan Sheet

Executive Summary

Sales exceeding $150 million in two weeks on retail shelves for OTC weight-loss drug alli figure prominently in GlaxoSmithKline's commitment to its consumer health care products division, senior executives say
Advertisement

Related Content

FDA Evaluates Alli For Potential Serious Risk Of Kidney Stones
FDA Evaluates Alli For Potential Serious Risk Of Kidney Stones
GSK Invests In Consumer Unit To Overcome Generic Threat, Low Alli Sales
Alli Sales Slender On Lower Retailer Demand, Flatten GSK Consumer Sales
Alli Sales Top 2 Million Starter Packs, Drive GSK’s OTC Sales
Alli Marketing Stresses Education, With Emphasis On Minority Groups – GSK
Sales & Earnings In Brief
Sales & Earnings In Brief
Alli Approved OTC For Weight Loss With “Goal Oriented” Indication
GSK Looks To Expand OTC Reach With CNS Brands

Topics

Advertisement
UsernamePublicRestriction

Register

PS100751

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel